PubRank

S E Kern

Author PubWeight™ 247.58‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genetic alterations during colorectal-tumor development. N Engl J Med 1988 26.82
2 Definition of a consensus binding site for p53. Nat Genet 1992 12.76
3 DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996 11.13
4 Gene expression profiles in normal and cancer cells. Science 1997 9.65
5 Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990 8.32
6 Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001 6.30
7 Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1998 5.88
8 Allelotype of colorectal carcinomas. Science 1989 5.54
9 Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994 4.63
10 Progression model for pancreatic cancer. Clin Cancer Res 2000 4.60
11 Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997 4.54
12 Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001 4.19
13 Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996 4.09
14 Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000 3.74
15 DPC4 gene in various tumor types. Cancer Res 1996 3.74
16 Scrambled exons. Cell 1991 3.65
17 Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996 3.60
18 Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 1991 3.59
19 Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997 3.17
20 The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001 3.02
21 Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 1998 2.89
22 p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997 2.88
23 p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994 2.80
24 The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev 1998 2.72
25 Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. Am J Pathol 2000 2.63
26 Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999 2.59
27 Genetic progression in the pancreatic ducts. Am J Pathol 2000 2.58
28 Mad-related genes in the human. Nat Genet 1996 2.51
29 Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001 2.50
30 Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994 2.26
31 Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res 1998 2.23
32 Allelotype of pancreatic adenocarcinoma. Cancer Res 1994 2.11
33 Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections. Am J Pathol 1997 2.08
34 Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001 1.98
35 Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998 1.97
36 Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res 2001 1.96
37 Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 2000 1.81
38 Colorectal neoplasia in juvenile polyposis or juvenile polyps. Arch Dis Child 1991 1.81
39 Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 1996 1.75
40 BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol 2000 1.72
41 Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res 1998 1.71
42 Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. Am J Pathol 2000 1.69
43 Remifentanil by bolus injection: a safety, pharmacokinetic, pharmacodynamic, and age effect investigation in human volunteers. Br J Anaesth 2004 1.62
44 Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 1996 1.57
45 Molecular pathology of pancreatic cancer. Cancer J 2001 1.56
46 Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci U S A 1998 1.55
47 A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res 2000 1.53
48 Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res 2001 1.49
49 Direct demonstration in intestinal secretions of an IgA memory response to orally administered Shigella flexneri antigens. J Immunol 1982 1.46
50 Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 1998 1.42
51 Wild-type, but not mutant, human p53 proteins inhibit the replication activities of simian virus 40 large tumor antigen. Proc Natl Acad Sci U S A 1990 1.39
52 Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev 1998 1.36
53 K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 1995 1.35
54 Nomenclature: vertebrate mediators of TGFbeta family signals. Cell 1996 1.34
55 Familial pancreatic cancer. Ann Oncol 1999 1.33
56 Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res 1992 1.31
57 Familial pancreatic cancer: a review. Semin Oncol 1996 1.30
58 Dpc4 transcriptional activation and dysfunction in cancer cells. Cancer Res 1998 1.29
59 ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci U S A 2001 1.29
60 Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology 1995 1.23
61 Progress in cancer genetics: lessons from pancreatic cancer. Ann Oncol 1999 1.22
62 Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells. Mol Carcinog 1999 1.20
63 p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995 1.20
64 G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: phenotypes reversed by a tumorigenic mutation. Proc Natl Acad Sci U S A 1999 1.19
65 Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer 1999 1.19
66 Tumor-suppressor genes in pancreatic cancer. J Hepatobiliary Pancreat Surg 1998 1.17
67 Efficacy of local dipyridamole therapy in a porcine model of arteriovenous graft stenosis. Kidney Int 2006 1.17
68 Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. Cancer Res 1996 1.14
69 Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol 2000 1.13
70 Pathology of incipient pancreatic cancer. Ann Oncol 1999 1.10
71 Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer 2001 1.05
72 Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin N Am 1998 1.05
73 Gastric antral vascular ectasia ("watermelon stomach"): radiologic findings. Radiology 1991 1.01
74 Genomic sequencing of DPC4 in the analysis of familial pancreatic carcinoma. Diagn Mol Pathol 1997 0.98
75 The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology 1992 0.97
76 Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies. Appl Immunohistochem Mol Morphol 2000 0.97
77 DPC4 gene mutation in colitis associated neoplasia. Gut 1997 0.96
78 The relationship of quantitative nuclear morphology to molecular genetic alterations in the adenoma-carcinoma sequence of the large bowel. Am J Pathol 1992 0.94
79 Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis. Genes Chromosomes Cancer 1999 0.92
80 High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells. Ann Surg 2001 0.91
81 Homozygous deletions inactivate DCC, but not MADH4/DPC4/SMAD4, in a subset of pancreatic and biliary cancers. Genes Chromosomes Cancer 2000 0.90
82 Klenow co-sequencing: a method for eliminating "stops". Biotechniques 1994 0.90
83 Local IgA-memory response to bacterial antigens. Ann N Y Acad Sci 1983 0.89
84 Molecular genetics and related developments in pancreatic cancer. Curr Opin Gastroenterol 1999 0.89
85 Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res 1998 0.88
86 The structural basis of molecular genetic deletions. An integration of classical cytogenetic and molecular analyses in pancreatic adenocarcinoma. Am J Pathol 1997 0.88
87 Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: analysis of progression and recurrence by DPC4 immunohistochemical labeling. Hum Pathol 2001 0.87
88 Bidirectional on/off switch for controlled targeting of proteins to subcellular compartments. J Control Release 2004 0.87
89 Functional mapping of the MH1 DNA-binding domain of DPC4/SMAD4. Nucleic Acids Res 2000 0.85
90 Bacterial overgrowth and mucosal changes in isolated (Thirty-Vella) ileal loops in rabbits. Effects of intraluminal antibiotics. Lab Invest 1987 0.85
91 Genomic FHIT analysis in RER+ and RER- adenocarcinomas of the pancreas. Genes Chromosomes Cancer 2000 0.85
92 Clinical trials in neonates: a therapeutic imperative. Clin Pharmacol Ther 2009 0.84
93 Genetic counseling and testing for germline p16 mutations in two pancreatic cancer-prone families. Gastroenterology 2000 0.84
94 Novel germline p16(INK4) allele (Asp145Cys) in a family with multiple pancreatic carcinomas. Mutations in brief no. 148. Online. Hum Mutat 1998 0.84
95 Clonality: more than just a tumor-progression model. J Natl Cancer Inst 1993 0.83
96 Cancer gets Mad: DPC4 and other TGFbeta pathway genes in human cancer. Biochim Biophys Acta 1996 0.83
97 Molecular genetics of exocrine pancreatic neoplasms. Surg Clin North Am 1995 0.83
98 An integrated high-resolution physical map of the DPC/BRCA2 region at chromosome 13q12. Cancer Res 1995 0.82
99 Population pharmacokinetic and pharmacodynamic models of remifentanil in healthy volunteers using artificial neural network analysis. Br J Clin Pharmacol 2007 0.81
100 p53: tumor suppression through control of the cell cycle. Gastroenterology 1994 0.81
101 Oncogenic levels of mitogen-activated protein kinase (MAPK) signaling of the dinucleotide KRAS2 mutations G12F and GG12-13VC. Hum Mutat 2001 0.80
102 Three cases of gastric spirochetelike organisms. Gastroenterology 1989 0.78
103 Novel homozygous deletions of chromosomal band 18q22 in pancreatic adenocarcinoma identified by STS marker scanning. Genes Chromosomes Cancer 1999 0.78
104 Evaluation in volunteers of the VIA V-ABG automated bedside blood gas, chemistry, and hematocrit monitor. J Clin Monit Comput 1998 0.78
105 Malignant fibrous histiocytoma of the heart presenting as unilateral pulmonary thromboembolism and infarct. Hum Pathol 1985 0.78
106 Use and benefits of a Web site for pancreatic cancer. JAMA 1998 0.77
107 Frequent germline deletion polymorphism of chromosomal region 8p12-p21 identified as a recurrent homozygous deletion in human tumors. Genomics 2001 0.77
108 High-resolution deletion mapping of chromosome arm 1p in pancreatic cancer identifies a major consensus region at 1p35. Genes Chromosomes Cancer 1999 0.77
109 Molecular genetics of ductal pancreatic neoplasia. Curr Opin Gastroenterol 2000 0.75
110 Isolation of YAC insert sequences by representational difference analysis. Nucleic Acids Res 1995 0.75
111 Molecular genetic alterations as potential prognostic indicators in colorectal carcinoma and molecular genetics of colorectal carcinoma. Cancer 1993 0.75
112 Influence of hemorrhagic shock on remifentanil: a pharmacokinetic and pharmacodynamic analysis. Anesthesiology 2001 0.75